Almirall and etherna announce a multi-target alliance to discover and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer.
The alliance combines and leverages etherna’s innovative proprietary mRNA capabilities and LNP formulations with Almirall’s leading expertise in medical dermatology to accelerate discovery of novel treatment options.
Delivery of LNP-formulated mRNA for transient and local translation of therapeutic proteins offers a unique opportunity to encode for multiple therapeutically active components in a single treatment.
Etherna and Almirall will work collaboratively on the research activities, while Almirall will lead clinical development and commercialisation.
Under the terms of the agreement, etherna will receive upfront and technology access payments. In addition, etherna is eligible to receive success-based development and commercial milestone payments that could exceed €300m contingent upon launch and commercial success of multiple products, as well as tiered royalties based upon future global sales. Further financial details were not disclosed.
Dr Karl Ziegelbauer, Chief Scientific Officer of Almirall, stated: “At Almirall, we always look for new solutions for patients suffering from skin diseases and we are thrilled about the strategic alliance with etherna to strengthen our pipeline with mRNA-based assets.”
Bernard Sagaert, CEO of etherna, stated: “We are excited to partner with Almirall to advance mRNA therapeutics into medical dermatology."
"Almirall and etherna share the vision that intradermal application of LNP-formulated mRNA is a highly promising strategy to bring novel, efficacious new treatment options that will deliver huge benefits to patients.”
